BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jang WS, Kim MS, Jeong WS, Chang KD, Cho KS, Ham WS, Rha KH, Hong SJ, Choi YD. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int 2018;121:225-31. [DOI: 10.1111/bju.13992] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Cheng B, Ye S, Bai P. The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis. World J Surg Oncol 2021;19:160. [PMID: 34051809 DOI: 10.1186/s12957-021-02265-8] [Reference Citation Analysis]
2 Mahjoub S, Heidenreich A. Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. Transl Androl Urol 2021;10:3167-75. [PMID: 34430419 DOI: 10.21037/tau-20-1033] [Reference Citation Analysis]
3 Martini A, Gandaglia G, Briganti A. What is new in robot-assisted radical prostatectomy: a narrative review. Current Opinion in Urology 2019;29:14-8. [DOI: 10.1097/mou.0000000000000564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
4 Motterle G, Ahmed ME, Andrews JR, Karnes RJ. The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients. Front Oncol 2019;9:1395. [PMID: 31921652 DOI: 10.3389/fonc.2019.01395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8. [PMID: 30266309 DOI: 10.1016/j.eururo.2018.09.008] [Cited by in Crossref: 165] [Cited by in F6Publishing: 144] [Article Influence: 41.3] [Reference Citation Analysis]
6 Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, Ost P, Rappe B, De Troyer B, Verbaeys C, Kimpe B, Billiet I, Plancke H, Fransis K, Willemen P, Ameye F, Decaestecker K, Lumen N. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int 2021. [PMID: 34289231 DOI: 10.1111/bju.15553] [Reference Citation Analysis]
7 Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. Eur Urol Oncol 2019;2:174-88. [PMID: 31017094 DOI: 10.1016/j.euo.2018.09.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
8 Sooriakumaran P. Surgery for oligometastatic prostate cancer: ready for prime time? BJU Int 2018;121:E7-8. [DOI: 10.1111/bju.14038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Chen H, Qu M, Lian BJ, Wang HF, Wang Y, Dong ZY, Zhu F, Shi ZK, Jia ZP, Sun YH, Gao X. Short-term therapeutic outcomes of robotic-assisted laparoscopic radical prostatectomy for oligometastatic prostate cancer: a propensity score matching study. Chin Med J (Engl) 2020;133:127-33. [PMID: 31880744 DOI: 10.1097/CM9.0000000000000590] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. Local treatment for metastatic prostate cancer: A systematic review. Int J Urol. 2018;25:390-403. [PMID: 29572963 DOI: 10.1111/iju.13535] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
11 Koo KC, Dasgupta P. Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review. Yonsei Med J 2018;59:567-79. [PMID: 29869454 DOI: 10.3349/ymj.2018.59.5.567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Miura N, Pradere B, Mori K, Mostafaei H, Quhal F, Misrai V, D'Andrea D, Albisinni S, Papalia R, Saika T, Scarpa RM, Shariat SF, Esperto F. Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. Minerva Urol Nefrol 2020;72:531-42. [PMID: 32550632 DOI: 10.23736/S0393-2249.20.03779-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer 2019;125:340-52. [PMID: 30521067 DOI: 10.1002/cncr.31860] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
14 Mistretta FA, Luzzago S, Conti A, Verri E, Marvaso G, Collà Ruvolo C, Catellani M, Di Trapani E, Cozzi G, Bianchi R, Ferro M, Cordima G, Brescia A, Cossu Rocca M, Mirone V, Jereczek-fossa BA, Nolè F, de Cobelli O, Musi G. Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone. Cancers 2022;14:2313. [DOI: 10.3390/cancers14092313] [Reference Citation Analysis]
15 Yang G, Xie J, Zhang S, Gu W, Yuan J, Wang R, Guo C, Ye L, Peng B, Yao X, Yang B. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy. Front Oncol 2022;11:812549. [DOI: 10.3389/fonc.2021.812549] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chi C, Fan L, Dong B, Zhu Y, Xin Z, Pan J, Xue W. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis. Clin Genitourin Cancer 2021;19:e223-34. [PMID: 33824096 DOI: 10.1016/j.clgc.2021.02.004] [Reference Citation Analysis]
17 Alvarez-Maestro M, Gomez Rivas J, Moschini M. Surgery for oligometastatic prostate cancer: Where are we going? Actas Urol Esp (Engl Ed) 2021;45:479-80. [PMID: 34330693 DOI: 10.1016/j.acuroe.2021.06.006] [Reference Citation Analysis]
18 Gîngu C, Heidenreich A, Andreşanu A, Mihancea A, Sinescu I, Baston C. Treatment of the primary in metastatic prostate cancer. Curr Opin Urol 2020;30:566-75. [PMID: 32452998 DOI: 10.1097/MOU.0000000000000779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Leyh-Bannurah SR, Wagner C, Schuette A, Liakos N, Karagiotis T, Mendrek M, Rachubinski P, Oelke M, Tian Z, Witt JH. Feasibility of robot-assisted radical prostatectomy in men at senior age ≥75 years: perioperative, functional, and oncological outcomes of a high-volume center. Aging Male 2022;25:8-16. [PMID: 34957914 DOI: 10.1080/13685538.2021.2018417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Nason GJ, Hamilton RJ. Treating the primary in metastatic prostate cancer: where do we stand? Current Opinion in Supportive & Palliative Care 2019;13:243-8. [DOI: 10.1097/spc.0000000000000432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Imber BS, Varghese M, Goldman DA, Zhang Z, Gewanter R, Marciscano AE, Mychalczak B, Gorovets D, Kollmeier M, McBride SM, Zelefsky MJ. Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer. Adv Radiat Oncol 2020;5:1213-24. [PMID: 33305082 DOI: 10.1016/j.adro.2020.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Connor MJ, Shah TT, Smigielska K, Day E, Sukumar J, Fiorentino F, Sarwar N, Gonzalez M, Falconer A, Klimowska-Nassar N, Evans M, Naismith OF, Thippu Jayaprakash K, Price D, Gayadeen S, Basak D, Horan G, McGrath J, Sheehan D, Kumar M, Ibrahim A, Brock C, Pearson RA, Anyamene N, Heath C, Shergill I, Rai B, Hellawell G, McCracken S, Khoubehi B, Mangar S, Khoo V, Dudderidge T, Staffurth JN, Winkler M, Ahmed HU. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 2021;11:e042953. [PMID: 33632752 DOI: 10.1136/bmjopen-2020-042953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As NJ, Lo SS, Moghanaki D, Loblaw A, Siva S. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. Curr Oncol Rep 2019;21. [DOI: 10.1007/s11912-019-0791-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
24 Liu S, Hemal A. Techniques of robotic radical prostatectomy for the management of prostate cancer: which one, when and why. Transl Androl Urol 2020;9:906-18. [PMID: 32420206 DOI: 10.21037/tau.2019.09.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. Clin Genitourin Cancer 2019;17:e939-45. [PMID: 31375352 DOI: 10.1016/j.clgc.2019.05.022] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Alvarez-maestro M, Gomez Rivas J, Moschini M. Cirugía del cáncer de próstata oligometastásico: ¿hacia dónde nos dirigimos? Actas Urológicas Españolas 2021;45:479-80. [DOI: 10.1016/j.acuro.2021.02.004] [Reference Citation Analysis]
27 Si S, Zheng B, Wang Z, Niu Z. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis. Prostate 2021;81:736-44. [PMID: 34056739 DOI: 10.1002/pros.24170] [Reference Citation Analysis]
28 Juan GR, Laura FH, Javier PV, Natalia VC, Mᵃ Isabel GR, Enrique RG, José Luis SP, Pablo AL, Noelia SS, Roser VD, Jesús M. Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review. Cancers 2022;14:2017. [DOI: 10.3390/cancers14082017] [Reference Citation Analysis]
29 Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol 2020;17:168-82. [PMID: 31712648 DOI: 10.1038/s41571-019-0284-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
30 Falagario U, Veccia A, Weprin S, Albuquerque EV, Nahas WC, Carrieri G, Pansadoro V, Hampton LJ, Porpiglia F, Autorino R. Robotic-assisted surgery for the treatment of urologic cancers: recent advances. Expert Rev Med Devices 2020;17:579-90. [PMID: 32342705 DOI: 10.1080/17434440.2020.1762487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Koh DH, Jang WS, Park JW, Ham WS, Han WK, Rha KH, Choi YD. Efficacy and Safety of Robotic Procedures Performed Using the da Vinci Robotic Surgical System at a Single Institute in Korea: Experience with 10000 Cases. Yonsei Med J. 2018;59:975-981. [PMID: 30187705 DOI: 10.3349/ymj.2018.59.8.975] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]